Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross
09:03am, Wednesday, 07'th Jan 2026
Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% i
Pre-Market Stock Futures: The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit another record high, closing over $49,000 for the
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?
05:02am, Wednesday, 07'th Jan 2026
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
My Top 5 Stocks to Buy in Early 2026
04:15am, Wednesday, 07'th Jan 2026
These stocks, ranging from technology to healthcare, could add diversification to your portfolio. Four have proven their earnings strength; the fifth makes a solid recovery story bet.
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
12:15pm, Tuesday, 06'th Jan 2026
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
America's new vaccine doctrine for children replaces data with dogma
11:55am, Tuesday, 06'th Jan 2026
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being
Tamboran advancing to full control of Falcon Oil & Gas Australia after shareholder approval
07:16am, Tuesday, 06'th Jan 2026
Tamboran Resources Corporation (ASX:TBN, NYSE:TBN, OTC:TBNRL) has moved a step closer to consolidating full ownership of Falcon Oil & Gas Australia Ltd...
Orthocell delivers record December quarter revenue
05:49am, Tuesday, 06'th Jan 2026
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has delivered record quarterly revenue of $3.2 million for the quarter ended December 31, 2025, supported by ongoing...
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
04:21pm, Monday, 05'th Jan 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) on Monday reiterated its 2025 revenue guidance of $1.6 billion to $2.0 billion and outlined its pipeline milestones for 2026-28, with the company continuing to foc
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
11:19am, Monday, 05'th Jan 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) on Monday reiterated its 2025 revenue guidance of $1.6 billion to $2 billion and outlined its pipeline milestones for...
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
07:00am, Monday, 05'th Jan 2026
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda
Bank Pictet & Cie Europe AG Has $8.39 Million Position in Moderna, Inc. $MRNA
03:28am, Friday, 02'nd Jan 2026
Bank Pictet and Cie Europe AG cut its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 55.7% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 324,6
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
06:45pm, Tuesday, 30'th Dec 2025
In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.
Cwm LLC Purchases 130,200 Shares of Moderna, Inc. $MRNA
04:08am, Monday, 29'th Dec 2025
Cwm LLC grew its position in Moderna, Inc. (NASDAQ: MRNA) by 50.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 390,333 shares of the c
Forget Moderna Stock, This is a Much Better Buy
10:10am, Saturday, 27'th Dec 2025
Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it's been on the rise. This other biotech has proven itself as a long-term winner.
